RecruitingNCT04503577

Prospective Bladder Cancer Infrastructure (ProBCI)

Prospective Bladder Cancer Infrastructure: an Infrastructure for Observational and Interventional Bladder Cancer Research (ProBCI)

Sponsor

Prospective Bladder Cancer Infrastructure Foundation

Enrollment

3,600 participants

Start Date

Oct 4, 2020

Study Type

OBSERVATIONAL

Conditions

Bladder Cancer

Summary

Prospective nation-wide cohort of high-risk non-muscle-invasive, muscle-invasive and metastatic bladder cancer in the Netherlands

Eligibility

Min Age: 18 Years

Plain Language Summary

Simplified for easier understanding

This is a research registry (not a treatment study) for people diagnosed with bladder cancer. By joining, you contribute biological samples and medical information that researchers can use to better understand bladder cancer and develop new treatments. **You may be eligible if...** - You have been diagnosed with bladder cancer - Your cancer is any stage except the earliest non-invasive stage (Ta) - You are 18 years or older - You are willing to sign a consent form **You may NOT be eligible if...** - Your only bladder cancer is stage Ta (the most superficial, non-invasive kind) - You are not willing or able to provide informed consent Note: Joining this registry does not prevent you from participating in other studies. Talk to your doctor to see if this trial is right for you.

This summary was AI-generated to explain the trial in plain language. It is not medical advice. Always discuss eligibility with your doctor before enrolling in a clinical trial.

Interested in this trial?

Get notified about updates and connect with the research team.

Locations(23)

Jeroen Bosch Hospital

's-Hertogenbosch, Netherlands

ZGT

Almelo, Netherlands

Meander Medical Center

Amersfoort, Netherlands

Amsterdam UMC, location VUMC

Amsterdam, Netherlands

Rijnstate

Arnhem, Netherlands

Amphia Ziekenhuis

Breda, Netherlands

Albert Schweitzer Hospital

Dordrecht, Netherlands

Ziekenhuis Gelderse Vallei

Ede, Netherlands

Treant Hospital

Emmen, Netherlands

University Medical Center Groningen

Groningen, Netherlands

Spaarne Gasthuis

Hoofddorp, Netherlands

Medisch Centrum Leeuwarden

Leeuwarden, Netherlands

Alrijne Ziekenhuis

Leiderdorp, Netherlands

Maastricht University Medical Center

Maastricht, Netherlands

Canisius Wilhelmina Ziekenhuis

Nijmegen, Netherlands

Radboud univerisity Medical Center

Nijmegen, Netherlands

Erasmus Medical Center

Rotterdam, Netherlands

Zuyderland

Sittard, Netherlands

Elisabeth-TweeSteden Ziekenhuis

Tilburg, Netherlands

University Medical Center Utrecht

Utrecht, Netherlands

VieCuri

Venlo, Netherlands

SKB Winterswijk

Winterswijk, Netherlands

Isala

Zwolle, Netherlands

View Full Details on ClinicalTrials.gov

For the most up-to-date information, visit the official listing.

Visit

NCT04503577

Related Trials

18F-Fibroblast Activation Protein Inhibitor ([18F]FAPI-74) PET Imaging for Cancer Detection

NCT065031461 location

Collection of Serum and Tissue Samples From Patients With Biopsy-Proved or Suspected Malignant Disease

NCT000268841 location

Evaluation for NCI Surgery Branch Clinical Research Protocols

NCT000018231 location

DESTINY-PANTUMOUR04

NCT0712400017 locations

A Clinical Trial of Sacituzumab Tirumotecan (Sac-TMT, MK-2870) to Treat Urothelial Cancer (MK-2870-031)

NCT0741929521 locations